GH Research (GHRS) Depreciation & Amortization (CF) (2021 - 2026)
GH Research (GHRS) posted quarterly Depreciation & Amortization (CF) of $88000.0 for Q4 2025, up 12.82% year-over-year from $78000.0 in Q4 2024, and down 1.12% quarter-over-quarter from $89000.0 in Q3 2025.
Powered by 
Analysis
GH Research (GHRS) Depreciation & Amortization (CF) (2021 - 2026) Analysis & Trends
GH Research's Depreciation & Amortization (CF) history runs 5 years deep, the most recent figure standing at $88000.0 for Q4 2025.
- In Q4 2025, Depreciation & Amortization (CF) rose 12.82% year-over-year to $88000.0; the TTM figure through Dec 2025 stood at $335000.0 (up 6.35% YoY), while the FY2025 annual figure was $335000.0, up 6.35% from the prior year.
- Depreciation & Amortization (CF) for Q4 2025 stood at $88000.0, down from $89000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $89000.0 in Q3 2025, with the low at $1000.0 in Q1 2021.
- The 5-year median for Depreciation & Amortization (CF) is $77500.0 (2023), against an average of $51550.0.
- The sharpest annual moves came in 2022 and 2025: Depreciation & Amortization (CF) soared 1000.0% in 2022, then retreated 5.0% in 2025.
- GH Research's Depreciation & Amortization (CF) stood at $9000.0 in 2021, then surged by 44.44% to $13000.0 in 2022, then soared by 500.0% to $78000.0 in 2023, then changed by 0.0% to $78000.0 in 2024, then advanced by 12.82% to $88000.0 in 2025.
- Business Quant data shows GHRS's Depreciation & Amortization (CF) at $88000.0 in Q4 2025, $89000.0 in Q3 2025, and $82000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | GH Research | 1.72 Bn | 1.36 Bn | - | 91,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 91,000.00 |
| Mar 31, 2026 | 91,000.00 |
| Dec 31, 2025 | 88,000.00 |
| Sep 30, 2025 | 89,000.00 |
| Jun 30, 2025 | 82,000.00 |
| Mar 31, 2025 | 76,000.00 |
| Dec 31, 2024 | 78,000.00 |
| Sep 30, 2024 | 79,000.00 |
| Jun 30, 2024 | 78,000.00 |
| Mar 31, 2024 | 80,000.00 |
| Dec 31, 2023 | 78,000.00 |
| Sep 30, 2023 | 80,000.00 |
| Jun 30, 2023 | 80,000.00 |
| Mar 31, 2023 | 77,000.00 |
| Dec 31, 2022 | 13,000.00 |
| Sep 30, 2022 | 12,000.00 |
| Jun 30, 2022 | 11,000.00 |
| Mar 31, 2022 | 11,000.00 |
| Dec 31, 2021 | 9,000.00 |
| Sep 30, 2021 | 6,000.00 |